Jagsonpal Pharmaceuticals Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.6%1-day move

₹182.98

prior close

₹182.75

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-0.2-0.7-0.3+1.1+1.6+1.2-0.6+1.1-0.3+1.1+6.0+6.1+8.7+14.5

Up moveDown movePending

AI summary

Jagsonpal Pharmaceuticals has received an assessment order from the Income Tax Department's Faceless Assessment Unit, dated March 12, 2026, for Assessment Year 2024-25. The order disallows certain expenses claimed in the company's tax return, resulting in a tax demand of Rs. 4,81,61,360 (approximately Rs. 4.82 crore) along with potential penalties. The company has stated it believes it has strong grounds to contest this and does not expect any material financial impact. It plans to file an appeal before the Appellate Authority within the prescribed timelines.

Likely market impact

Near-term negative sentiment possible due to the tax demand, but the company has signaled confidence in its appeal and minimal financial impact. Investors should watch the appeal outcome as a final adverse ruling could affect earnings and cash flows.